BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)
Shots:
- The US FDA has approved Opdivo + Pt-doublet CT as neoadj. followed by Opdivo alone as adj. treatment of resectable (tumors ≥4 cm and/or node+) NSCLC without any known EGFR mutations/ALK rearrangements, supported by the P-III (CheckMate-77T) study
- The P-III (CheckMate-77T) study investigated neoadj. Opdivo (360mg, Q3W, 4 cycles) & CT combination followed by surgery & Opdivo (480mg, Q4W, ~1yr.) alone as adj. vs CT & PBO to treat patients (n=461) with resectable NSCLC
- Study depicted a 42% reduction in the risk of disease recurrence, progression or death at a median follow-up of 25.4mos., 18mos. EFS was observed in 70% vs 50% & pCR was found in 25% vs 4.7% among the ITT population
Ref: BMS | Image: BMS
Related News:- BMS Reports the EMA’s Validation of Application for Opdivo Plus Yervoy to Treat Hepatocellular Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
